Kartos Therapeutics

French Biotech Company Ipsen to Buy Kartos Therapeutics for $450 Million

French biotech firm Ipsen agreed to acquire U.S.-based Kartos Therapeutics for $450 million to expand its oncology pipeline with late-stage blood cancer treatment navtemadlin. The transaction includes